pertuzumab

Details

Key Milestones2
Call for patient/clinician/industry input open 9-Jan-25
Call for patient/clinician/industry input closed 3-Mar-25
Review initiated14-Feb-25
Expert committee meeting (initial)17-Jul-25

inavolisib

Details

Key Milestones2
Call for patient/clinician input openJanuary 08, 2025
Call for patient/clinician input closedMarch 03, 2025
Submission receivedFebruary 19, 2025
Submission acceptedMarch 05, 2025
Review initiatedMarch 06, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 23, 2025
Deadline for sponsors commentsJune 03, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJune 26, 2025
Expert committee meeting (initial)July 09, 2025
Draft recommendation issued to sponsorJuly 21, 2025
To
July 23, 2025
Draft recommendation posted for stakeholder feedbackJuly 31, 2025
End of feedback periodAugust 15, 2025

venetoclax

Details

Key Milestones2
Call for patient/clinician input open08-Jan-25
Call for patient/clinician input closed03-Mar-25
Submission received20-Feb-25
Submission accepted06-Mar-25
Review initiated07-Mar-25
Draft CADTH review report(s) provided to sponsor for comment26-May-25
Deadline for sponsors comments04-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor26-Jun-25
Expert committee meeting (initial)09-Jul-25
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-

abemaciclib

Details

Key Milestones2
Call for patient/clinician input open08-Jan-25
Call for patient/clinician input closed03-Mar-25
Submission received14-Feb-25
Submission accepted11-Mar-25
Clarification:

- Submission was not accepted for review on 03 Mar 2025

Review initiated12-Mar-25
Draft CADTH review report(s) provided to sponsor for comment26-May-25
Deadline for sponsors comments04-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor26-Jun-25
Expert committee meeting (initial)09-Jul-25
Draft recommendation issued to sponsorJuly 21, 2025
To
July 23, 2025
Draft recommendation posted for stakeholder feedback31-Jul-25
End of feedback period15-Aug-25

teplizumab

Details

Key Milestones2
Call for patient/clinician input openJanuary 08, 2025
Call for patient/clinician input closedMarch 03, 2025
Submission receivedFebruary 19, 2025
Submission acceptedMarch 05, 2025
Review initiatedMarch 06, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 23, 2025
Deadline for sponsors commentsJune 03, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 11, 2025
Expert committee meeting (initial)July 23, 2025
Draft recommendation issued to sponsorAugust 05, 2025
To
August 07, 2025
Draft recommendation posted for stakeholder feedbackAugust 14, 2025
End of feedback periodAugust 28, 2025

abemaciclib

Details

Key Milestones2
Call for patient/clinician input open08-Jan-25
Call for patient/clinician input closed03-Mar-25
Submission received14-Feb-25
Submission accepted03-Mar-25
Review initiated04-Mar-25
Draft CADTH review report(s) provided to sponsor for comment26-May-25
Deadline for sponsors comments04-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor26-Jun-25
Expert committee meeting (initial)09-Jul-25
Draft recommendation issued to sponsorJuly 21, 2025
To
July 23, 2025
Draft recommendation posted for stakeholder feedback31-Jul-25
End of feedback period15-Aug-25

osimertinib

Details

Key Milestones2
Call for patient/clinician input openJanuary 02, 2025
Call for patient/clinician input closedFebruary 24, 2025
Submission receivedFebruary 13, 2025
Submission acceptedFebruary 28, 2025
Review initiatedMarch 03, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 20, 2025
Deadline for sponsors commentsMay 29, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJune 26, 2025
Expert committee meeting (initial)July 09, 2025
Draft recommendation issued to sponsorJuly 21, 2025
To
July 23, 2025
Draft recommendation posted for stakeholder feedbackJuly 31, 2025
End of feedback periodAugust 15, 2025